An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

HIV incidence in sub-Saharan Africa has declined substantially, according to both UNAIDS estimates and empirical data pulled ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Without public health surveillance, officials trying to tackle outbreaks, identify threats and evaluate treatments are working ‘in the darkness of ignorance.’ ...

This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of ...

A groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt cut in funding from the United States government. As a result, several promising ...

Why is AIDS a syndrome and not a disease? What is syndrome?Lookman (by SMS) AIDS is the result of untreated HIV (Human Immunodeficiency Virus). Over time, HIV destroys CD4-T white blood cells, ...

In his Tuesday address to Congress, President Trump listed U.S.-funded programs that he considers an "appalling waste" — ...

Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.

Antiretroviral drugs are used to treat HIV infection. They work by blocking a stage of the virus's life cycle and, by doing so, prevent the virus from replicating. The drugs are organized into six ...